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Summary The aim of the present study was to analyse in invasive carcinomas of the uterine cervix, the
anionic glutathione S transferase (GSTi) gene, possibly implicated in the drug resistance of human cancers.
Total RNA preparations obtained from invasive cervical cancers (106 specimens), carcinomas in situ (CIS)
(three specimens) and normal cervical epitheliums (24 specimens) were analysed by Northern and slot blot
hybridisation. A 0.7 kb GSTi transcript band was detected in all the cervical specimens. GSTi mRNA levels
were lower in normal cervix (mean: 0.7 ±0.1 arbitrary units) than in invasive carcinomas (mean: 2.5 ± 1.5
units) (Student test P< 10-4). However no significant difference was observed between invasive cancers of
advanced stages (III and IV) and those of early stages (I and II). The presence of human papillomavirus in
cancers and in normal cervices did not influence significantly the GSTi mRNA level. Neither amplification nor
gross rearrangement of GSTi gene could be observed after Southern blot analysis of genomic DNA. In
conclusion, our data indicate that the presence of high levels of GSTi transcripts in invasive cancers may be a
consequence of the multiple biochemical changes which accompany cervical carcinogenesis.
The development of simultaneous resistance to structurally
unrelated drugs is a major obstacle to chemical treatment of
numerous cancers. In vitro studies performed in tumour cell
lines resistant to antitumour drugs showed that several inter-
related mechanisms could be involved in the resistance pro-
cess (Pastan & Gottesman, 1987; Moscow & Cowan, 1988;
Endicott & Ling, 1989; D'Arpa & Liu, 1989; Beck, 1989;
Giovanella et al., 1989; Tew, 1989). For example, a P-170
kDa transmembrane glycoprotein coded by a multidrug resis-
tance (MDRI) gene is present at high levels in cell lines that
are cross-resistant to anthracyclines and Vinca alkaloids (Pas-
tan & Gottesman, 1987; Moscow & Cowan, 1988; Endicott
& Ling, 1989). P-glycoprotein acts as a drug efflux pump
regulating intracellular accumulation of these drugs. DNA
topoisomerases I and II are nuclear enzymes important for
solving topological problems arising during DNA replication
and transcription (D'Arpa & Liu, 1989). These enzymes have
been shown to represent important targets for a variety of
anticancer drugs and to play a part in resistance process of
cancer cells (Beck, 1989; Giovanella et al., 1989). Another
mechanism of action involving glutathione S transferase was
described in cancer cells resistant to drugs as different as
cis-platinum, alkylating agents and anthracyclines (Tew,
1989). The anionic isoenzyme glutathione S transferase
(GSTx) which belongs to a complex group of drug-detoxify-
ing enzymes, was present at high levels in the MCF7 breast
cancer cell line resistant to Doxorubicine (DXR) together
with high levels of MDRI transcripts (Batist et al., 1986;
Moscow et al., 1988). Although the precise role of GST7 in
the development of resistance is not known, its expression
may be one among the numerous phenotypic and biochemi-
cal changes which accompany drug resistance in some
cancers.
Patients with invasive carcinoma of the uterine cervix are
treated by surgery, radiation and/or chemotherapy (Fried-
lander et al., 1983; McGuire et al., 1989). Until now, results
obtained with chemical agents suggest that cervical cancers
may exhibit a resistance phenotype. Therefore, the aim of
this study was to analyse the expression of the GSTi gene in
invasive cervical cancers of different clinical stages and of
different histological types in comparison with normal cer-
vical epitheliums. Such studies may contribute to a better
comprehension of the failure of drug therapy in cervical
cancers.
Materials and methods
Cervical cancers andnormal cervical epitheliums
One hundred and six specimens of invasive cervical cancer
were obtained by biopsy or rarely by surgical excision from
untreated patients (93 primary tumours and 5 node metas-
tases) and from treated patients (six recurrent tumours and
two liver metastases). These treated patients have received
external beam radiotherapy (RX) and/or drug regimen (DR)
composed of cis-platinum, Methotrexate, Chlorambucil and
Vincristine (Table I). Three specimens of carcinoma in situ
(CIS) were also obtained at surgery. Specimens of normal
cervical epithelium were obtained from 18 patients treated by
surgery for fibroma of the uterine corpus and from six
patients with adjacent primary cervical cancers. Tumour and
cell samples were immediately stored in liquid nitrogen.
DNA and RNA preparations
DNAs and total RNAs were prepared from the same tissue
samples (about 100 mg) by the guanidinium isothiocyanate-
CsCl gradient method (Maniatis et al., 1982; Sheng et al.,
1990). Briefly, tissues were ground in liquid nitrogen, then
lysed in the guanidinium-isothiocyanate buffer. Lysate was
layered onto a 5.7 M CsCl cushion and submitted to a centri-
fugation at 37 000 r.p.m. for 17 h at 20°C (SW55 Rotor
Beckman Ultracentrifuge model L5). DNA was collected
from the supernatant, dialysed and treated with proteinase
K. After deproteinisation by phenol-CHCI3, DNA was pre-
cipitated by absolute ethanol. DNA preparations in solution
in appropriate buffers, were incubated with HindIII restric-
tion endonuclease and the digest products analysed by
Southern blot hybridisation under stringent conditions using
human DNA probes.
Total RNA was collected at the bottom of the centrifuge
tube, solubilised in Tris EDTA, 0.1% SDS and precipitated
by absolute alcohol. RNA in solution in suitable buffer was
then incubated with 2 fig ml-' of DNAase RNAase-free
(Sigma) for 60 min, at 37°C. Denatured RNA samples (10 ,.g
per well) were fractionated on a formaldehyde 1.2% agarose
gel and transferred to a Hybond C extra filter and analysed
by Northern blot hybridisation. The quality of the RNA was
verified by the integrity of the 28S and 18S ribosomal bands
coloured by ethidium bromide.
Quantitation ofGSTrc transcripts
Serial 2-fold dilutions of total RNA (5, 2.5 and 1.25 tg) were
applied to a nitrocellulose filter using a glot blot apparatus
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Table I Expression of GSTi mRNA in cervical carcinomas and normal epitheliums of the uterine cervix
GSTi mRNA levels (mean in arbitrary units±standard deviation)
Specimens Total no Total Stage Pa Stage Ila Stage IIP Stage IVr Mb Rc
Squamous cell carcinomad 90 2.6 (±1.5) 2.1 (±1.2) 2.9 (±1.5) 2.8 (±1.4) 2.8 (± 1.0) 4.8 (± 3.0) 2.6 (±0.9)
Adenocarcinoma 14 1.7 (± 1.3) 1.4(± 1.8) 1.6 (± 1.2) 1.0(± 1.5) 3.2(±2.4)
Anaplastic cell carcinoma and 2 0.5 0.5 0.5
sarcomae
CIS 3 1.3 (±0.8)
Normal cervical epithelium 24 0.7 (±0.1)
aClinical stage according to the FIGO(Federation Internationale desGynecologuesObstetriciens) classification. The numberofprimary tumours
corresponding to the different clinical stages, aregiven in Figure 3. bMetastases, fivepelviclymph node metastases and two liver metastases. The two
liver metastases were obtained after patients were treated for primary tumour by vincristine (VCR) or external beam + radiotherapy (RX) and
chemotherapy (DR). cLocal recurrences (6 cases) after therapeutic failure (DX + DR). dTwo carcinoma specimens were obtained from the same
patient in four cases. eAnaplastic cell carcinoma was of stage III and sarcoma of stage I.
(Schleicher & Schuell). Hybridisation were performed in
stringent conditions with the appropriate denatured human
probes 32P-labelled by nick-translation (about iO0 c.p.m.).
Filters were exposed for various periods of times to Kodak
XAR5 films. The cervical cancer cell line CaSki (American
Type Culture Collection) was used to quantitate the levels of
GSTir mRNAs. The GSTi transcript level in this cell line
was stable and arbitrarily considered as the basic level (one
unit). GSTIE mRNA levels were determined by densitometer
scanning of the autoradiographic bands (Chromoscan 3,
Joyce Loebl). In order to provide a control for the amount of
RNA on the filters, the GSTn gene signal was removed and















The probe used was the 0.75 kb cDNA fragment of the
human GSTit gene (Batist et al., 1986).
Statistical analysis
The Student test was performed for comparison of mean
values, and the Chi-square test for other correlations.
Results
Analysis oftotal RNAfor GSTrc transcripts
Using the GSTi probe, a 0.7 kb transcript band was
observed in the 51 specimens of invasive carcinoma as well as
in the 12 specimens of normal cervical epitheliums which
were analysed by Northern blot hybridisation (Figure 1). The
analysis of total RNAs from the breast cancer cell lines
MCF7 sensitive (MCF7/p) and resistant to doxorubicin
(MCF7/DXR) provided negative and positive controls for
GSTir mRNA as previously described (Batist et al., 1986)
(Figure 1). The transcript levels given in arbitrary units were
quantitated by slot blot hybridisation relatively to the GSTir
mRNA level found in the uterine cervix carcinoma cell line,
CaSki, as described in Materials and methods. A representa-
tive slot blot is shown in Figure 2. The values of the GSTr
mRNA levels found in individual cervical specimens are
scored in Figure 3. High GSTt mRNA levels were found in
invasive squamous cell carcinomas (mean: 2.6 ± 1.5) while
low levels were detected in normal cervical epitheliums
(mean: 0.7±0.1) (Student test P<10-a). Levels were also
low in anaplastic cell carcinoma and sarcoma (0.5 unit)
(Table I). Intermediary GSTi mRNA levels were found in
adenocarcinomas (1.7 ± 1.3) and carcinomas in situ (1.3 ±
0.8) (Table I). An overexpression (level superior to 1 unit) of
the GSTn gene was observed in 89/106 (84%) invasive
cancers while observed only in 1/24 (4%) normal cervical
epithelium (P< 10-4). As shown in Figure 3, the frequency
of invasive cancers exhibiting an overexpressed GSTi gene
was significantly higher in squamous cell carcinomas (P<
0.01) than in cancers of other histological types (adenocar-
cinomas, anaplastic cell carcinoma and sarcoma). However
data showed that overexpression was not found to be differ-
ent in early stages (I and II) and in advanced stages (III and
GSTr -0.7 kb
Figure 1 Northern blot analysis of total RNA (10 gg in each
well) for analysis of GSTin transcripts. CaSki, MCF7/p, MCF7/
DXR cell lines, normal cervical epitheliums (NC), invasive
squamous cell carcinomas (T, primary tumour). No GSTi tran-
script was detected in MCF7/p and a high level was found in
MCF7/DXR as previously described (Batist et al., 1986). Upper
panel represents the transferred blots after the agarose gel was
coloured with ethidium bromide (EB). Exposure time to Kodak
XAR5 films was days.
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Figure 2 Slot blot analysis of total RNA from CaSki, MCF7/p,
MCF7/DXR cell lines, normal cervical epithelium (NC), invasive
squamous cell carcinomas of the uterine cervix (T, primary
tumour; M, liver metastasis; LN, lymph node metastasis; R,
recurrent tumour). Filter was hybridised using GSTh probe.
Three pairs of specimens obtained from the same patients were
shown; NC-T (0.5 and 1.2 units respectively); T-M (3.5 and 8.4
units respectively); T-LN (2.9 and 2.5 units respectively). Filter
was dehybridised and rehybridised using actin probe. Exposure
time to Kodak XAR5 film was two days for both signals.
IV) (Table I). The GSTIC mRNA levels were not found to be
significantly higher in recurrent tumours and lymph node
metastases than in primary tumours. However, in the case of
one liver metastasis treated with VCR, the GSTi mRNA
level was found higher (8.5 units) than that observed in theGST it mRNA IN CERVICAL CANCER AND NORMAL CERVIX 193
ed (data not shown). No evidence for amplification of the
GSTc gene was found in the 49 DNA preparations analysed
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Figure 3 Levels of GSTn mRNA in normal cervices (NC),
carcinomas in situ (CIS), invasive squamous cell carcinomas
(SCCa) of different clinical stages, 6 recurrent tumours (R) and 7
metastases (M) and invasive cervical cancers of other histological
types (ADCa) (14 adenocarcinomas, one anaplastic cell carcin-
oma and one sarcoma). Specimens with GSTr mRNA values> 1
unit (value found in CaSki cell line) were considered to contain
overexpressed GSTin gene.
untreated primary tumour (3.5 units) (Figure 2).
A previous immunohistochemical study (Shiratori et al.,
1987) had suggested that the human papillomavirus (HPV), a
virus most likely involved in the carcinogenesis of cervical
cancers (Zur Hausen, 1989), could favour the production of
GSTc in precancerous cervical lesions. Therefore we have
analysed the GSTc mRNA level in relation to the presence
of HPV DNA sequences in tumours and normal cervical
epitheliums. Of the 96 invasive cervical cancers for which
both HPV detection (Riou et al., 1990a) and GSTi analysis
could be done, no difference in GSTi mRNA levels was
found between HPV-positive (85% of tumours) and HPV-
negative tumours. For epidermoid carcinomas, the mean
levels of GSTi mRNA were 2.6 U for both HPV-positive
and HPV-negative tumours. For adenocarcinomas these
mean levels were 1.6 and 2.2 for HPV-positive and HPV-
negative tumours respectively. Moreover the GSTic mRNA
level was not found to be significantly higher in the four
HPV-positive than in the 11 HPV-negative normal cervices.
The normal cervical epithelium which displays more than 2
units (Figure 3) was HPV-negative.
Analysis of tumoral DNA for GSTit gene amplification
Forty-nine preparations of genomic DNA from cervical
cancers (40 samples) and normal cervices (nine samples) were
analysed by Southern blot hybridisation using GSTic probe.
As expected, two DNA bands of 6.2 and 5.0 kb were observ-
Cervical cancers are treated by surgery, radiation and cyto-
toxic drugs (Friedlander et al., 1983; Haie et al., 1988;
McGuire et al., 1989). Treatment depends on prognosis
which is determined by clinicopathological parameters of
which the most important are clinical stage at diagnosis and
nodal status (Pejovic et al., 1981). However in most cases,
cervical cancers respond poorly to chemotherapy. Therefore,
the present study was designed to test whether the GSTt
gene, suspected of involvement in drug resistance, was over-
expressed in cervical cancer cells.
Using Northern blot hybridisation techniques we detected
in the cervical tissues the expected 0.7 kb GSTc transcript
band (Figure 1). Transcripts were easily detectable in all the
specimens analysed. When normalised to actin mRNA,
GSTi transcript levels in squamous cell carcinomas were
found to undergo variations (range 0.5 to 8 units), but no
significant difference was observed between cancers of differ-
ent clinical stages suggesting that GSTi is not associated
with the progression of cervical cancers. In one liver metas-
tasis the GSTic mRNA level was found to be higher than in
the primary tumour. This could however be due to the
presence of normal tissue in the primary tumour. A signi-
ficant difference of the frequency of tumours with GSTic
overexpression (P<0.01) was found between squamous cell
carcinomas and cancers of other histological types (adenocar-
cinomas, anaplastic cell carcinoma and sarcoma).
Our data confirmed previous immunohistochemical studies
(Shiratori et al., 1987) showing a GSTn expression in about
90% of invasive cervical cancers. However they differ from
those of Shiratori et al. (1987) since the presence of GSTx
transcripts was detected in all invasive cervical cancer as well
as in all normal cervical epitheliums. Moreover we show that
the presence of HPV DNA sequences in invasive cervical
cancers and in normal cervical epitheliums does not influence
the GSTn mRNA level.
The overexpression of the GSTi gene found in most inva-
sive cervical cancers indicates that this gene is associated with
the process of carcinogenesis. Such gene activation is more
prevalent in squamous cell carcinomas than in adenocar-
cinomas. This is in accordance with the fact that squamous
cell carcinomas are usually less sensitive to cytotoxic drugs
than cancers of other histological types. In previous studies
we have shown the presence of MDRI transcripts at low, but
significant levels in 43% of invasive cervical cancers and in
68% of normal cervical epitheliums (Riou et al., 1990b)
suggesting that expression of this gene may also be involved
in the drug resistance phenotype of certain cervical cancers.
In conclusion, it is most likely that several mechanisms are
involved in the drug resistance of invasive cervical cancers.
The presence of high GSTic mRNA levels may be a conse-
quence of multiple biochemical alterations which accompany
carcinogenesis and indirectly lead to a drug resistant pheno-
type.
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